Literature DB >> 18650410

Clinicopathologic correlation and outcome of C1q nephropathy.

Satoshi Hisano1, Yuko Fukuma, Yoshie Segawa, Kazuhiko Niimi, Yoshitsugu Kaku, Ken Hatae, Takao Saitoh, Morishige Takeshita, Hiroshi Iwasaki.   

Abstract

BACKGROUND AND OBJECTIVES: The number of patients with C1q nephropathy (C1qN) in previous reports is small and the duration of follow-up is short. Our study describes the clinicopathologic correlation and clinical outcome through the mean follow-up period of 7.2 yr in 61 patients. DESIGN, SETTINGS, PARTICIPANTS, & MEASUREMENTS: Sixty-one patients, 1 to 67 yr of age, with C1qN were enrolled in this study.
RESULTS: According to presentation at onset, patients were divided into two groups: asymptomatic urinary abnormalities (asymptomatic) (n = 36) and nephrotic syndrome (NS) (n = 25). Light microscopy showed minimal change disease (MCD) in 46 patients (75%), mesangial proliferative glomerulonephritis in 7 (12%), and focal segmental glomerulosclerosis (FSGS) in 8 (13%). The prevalence of MCD was higher in the NS group than in the asymptomatic group. Nine patients in the asymptomatic group and all patients in the NS group were treated with prednisolone and/or cyclosporine. Normal urinalysis was found in 10 patients in asymptomatic group and 8 in NS group during the follow-up. Thirteen patients in the NS group were frequent relapsers at the latest follow-up. Three patients with FSGS developed chronic renal failure 8 to 15 yr after the diagnosis. C1q deposits disappeared in 3 of 8 patients receiving repeat biopsy, and 2 of these 3 showed FSGS.
CONCLUSIONS: The prognosis of C1qN is good, associated with MCD in a large number. In some patients, C1q deposits disappear through the follow-up period. FSGS may develop in some patients on repeat biopsies. Further investigation is critically needed to settle this issue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650410      PMCID: PMC2572272          DOI: 10.2215/CJN.00830208

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  19 in total

1.  Report of the task force on blood pressure control in children.

Authors:  S Blumenthal; R P Epps; R Heavenrich; R M Lauer; E Lieberman; B Mirkin; S C Mitchell; V Boyar Naito; D O'Hare; W McFate Smith; R C Tarazi; D Upson
Journal:  Pediatrics       Date:  1977-05       Impact factor: 7.124

2.  C1q nephropathy presenting as rapidly progressive crescentic glomerulonephritis.

Authors:  T Srivastava; V Chadha; E M Taboada; U S Alon
Journal:  Pediatr Nephrol       Date:  2000-09       Impact factor: 3.714

3.  An overlapping syndrome of IgA nephropathy and lipoid nephrosis.

Authors:  K N Lai; F M Lai; K W Chan; C P Ho; A C Leung; J Vallance-Owen
Journal:  Am J Clin Pathol       Date:  1986-12       Impact factor: 2.493

4.  The nephrotic syndrome in IgA glomerulonephritis: response to corticosteroid therapy.

Authors:  J Mustonen; A Pasternack; I Rantala
Journal:  Clin Nephrol       Date:  1983-10       Impact factor: 0.975

5.  C1q nephropathy: a variant of focal segmental glomerulosclerosis.

Authors:  Glen S Markowitz; Joshua A Schwimmer; M Barry Stokes; Samih Nasr; Robert L Seigle; Anthony M Valeri; Vivette D D'Agati
Journal:  Kidney Int       Date:  2003-10       Impact factor: 10.612

6.  Clinicopathologic correlation of C1q nephropathy in children.

Authors:  Yuko Fukuma; Satoshi Hisano; Yoshie Segawa; Kazuhiko Niimi; Noboru Tsuru; Yoshitsugu Kaku; Ken Hatae; Yasuhiro Kiyoshi; Akihisa Mitsudome; Hiroshi Iwasaki
Journal:  Am J Kidney Dis       Date:  2006-03       Impact factor: 8.860

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome.

Authors:  J C Jennette; C G Hipp
Journal:  Am J Kidney Dis       Date:  1985-08       Impact factor: 8.860

9.  Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  Kidney Int       Date:  1978-02       Impact factor: 10.612

10.  Immunohistopathologic evaluation of C1q in 800 renal biopsy specimens.

Authors:  J C Jennette; C G Hipp
Journal:  Am J Clin Pathol       Date:  1985-04       Impact factor: 2.493

View more
  10 in total

1.  Positive C1q staining associated with poor renal outcome in membranoproliferative glomerulonephritis.

Authors:  Takashi Takei; Mitsuyo Itabashi; Takahito Moriyama; Ari Shimizu; Yuki Tsuruta; Ayami Ochi; Kayu Nakayama; Chihiro Iwasaki; Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2012-07-21       Impact factor: 2.801

2.  Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy.

Authors:  Aditi Sinha; Cynthia C Nast; Ionut Hristea; Ashley A Vo; Stanley C Jordan
Journal:  Clin Exp Nephrol       Date:  2010-11-25       Impact factor: 2.801

3.  C1q nephropathy in children: clinical characteristics and outcome.

Authors:  Vindya N Gunasekara; Neil J Sebire; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

Review 4.  Current status and issues of C1q nephropathy.

Authors:  Akiko Mii; Akira Shimizu; Yukinari Masuda; Emiko Fujita; Kaoru Aki; Masamichi Ishizaki; Shigeru Sato; Adam Griesemer; Yuh Fukuda
Journal:  Clin Exp Nephrol       Date:  2009-04-17       Impact factor: 2.801

5.  Detection of De Novo PAX2 Variants and Phenotypes in Chinese Population: A Single-Center Study.

Authors:  Hua-Ying Xiong; Yong-Qi Shi; Cheng Zhong; Qin Yang; Gaofu Zhang; Haiping Yang; Daoqi Wu; Yaxi Chen; Qiu Li; Mo Wang
Journal:  Front Genet       Date:  2022-03-31       Impact factor: 4.772

6.  C1q nephropathy: a true immune complex disease or an immunologic epiphenomenon?

Authors:  Mordi Muorah; Manish D Sinha; Catherine Horsfield; Patrick J O'Donnell
Journal:  NDT Plus       Date:  2009-05-09

7.  Resolution of C1q deposition but not of the clinical nephrotic syndrome after immunomodulating therapy in focal sclerosis.

Authors:  Tibor Tibor Fülöp; Éva Csongrádi; Anna A Lerant; Matthew Lewin; Jack R Lewin
Journal:  J Nephropathol       Date:  2015-04-01

8.  C1q nephropathy in adults is a form of focal segmental glomerulosclerosis in terms of clinical characteristics.

Authors:  Kipyo Kim; Hyung-Eun Son; Ji-Young Ryu; Hajeong Lee; Seung Hyeok Han; Dong-Ryeol Ryu; Jin Ho Paik; Sejoong Kim; Ki Young Na; Dong-Wan Chae; Ho Jun Chin; Se Won Oh
Journal:  PLoS One       Date:  2019-04-19       Impact factor: 3.240

Review 9.  Diverse clinical and histology presentation in c1q nephropathy.

Authors:  Pavan Malleshappa; Mahesha Vankalakunti
Journal:  Nephrourol Mon       Date:  2013-06-25

Review 10.  C1q Nephropathy: The Unique Underrecognized Pathological Entity.

Authors:  Joe Devasahayam; Gowrishankar Erode-Singaravelu; Zeenat Bhat; Tony Oliver; Arul Chandran; Xu Zeng; Paramesh Dakshinesh; Unni Pillai
Journal:  Anal Cell Pathol (Amst)       Date:  2015-11-10       Impact factor: 2.916

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.